ArticleCancer2025
Improved survival with elevated BMI following immune checkpoint inhibition across various solid tumor cancer types.
Article in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Circulating Glypican 4 and mortality risk in patients with metastatic breast cancer-results from the DESIREE study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Association Between BMI and Tumour Regression After Neoadjuvant Therapy in Oesophageal Cancers: Insights From a German Nationwide Registry.Cancer medicine · 2026Article
- Association of subcutaneous adiposity with survival outcomes in advanced biliary tract cancer treated with gemcitabine, cisplatin, and immune checkpoint inhibitor.Journal of gastroenterology · 2026Article
- Does the obesity paradox truly exist? A study on the relationship between different degrees of obesity and stroke incidence and mortality based on the UK Biobank.BMC public health · 2026Article
- GLP-1 receptor agonists in patients with cancer are associated with reduced all-cause mortality and hospitalization.The Journal of clinical endocrinology and metabolism · 2026Article
- Obesity-derived metabolites modulate anti-tumor immunity in the tumor microenvironment: from mechanisms to clinical applications.BMC medicine · 2026Review
- Reassessing prognostic markers in metastatic renal cell carcinoma in the era of immune checkpoint inhibitors: the enduring value of body composition, nutritional, and inflammatory indices.International journal of clinical oncology · 2026Article
- Risk Factors for Adverse Outcomes in Cancer Patients With Sepsis.Journal of clinical medicine research · 2026Article
- Obesity: current developments in mechanisms, diagnosis, classification and the evolution of personalized management.Medical review (2021) · 2026Review
- Real-world effectiveness of first-line immunotherapy with or without chemotherapy versus chemotherapy alone in advanced non-small cell lung cancer.Frontiers in immunology · 2026Article
- Obesity, chronic breast inflammation and carcinogenesis: Molecular pathways and clinical implications (Review).International journal of oncology · 2026Review
- Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario?Frontiers in immunology · 2026Article
- Macrophages in obesity-related breast cancer: mechanistic insights and therapeutic opportunities.Breast cancer research : BCR · 2025Review
- Glucagon-like peptide-1 receptor agonism improves lung cancer outcomes and tumor growth control.JCI insight · 2025Article
- Association of lipid accumulation product with the prevalence and incidence of sarcopenia: a nationwide study in Chinese.Nutrition & metabolism · 2025Article
- Improved survival with elevated BMI following immune checkpoint inhibition across various solid tumor cancer types.Cancer · 2025Article
- Efficacy prediction of neoadjuvant cadonilimab plus FLOT therapy for advanced gastric cancer: a study based on body composition changes.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
INTRODUCTION/
backgroundObesity is a well-known risk factor for various cancers, yet emerging research demonstrates its association with improved survival outcomes in cancer treatment, labeled as "the obesity paradox." Studies investigating the clinical benefits of obesity across various cancer types after immune checkpoint inhibition (ICI) are limited.
methodsData were queried from the TriNetX database to identify patients with solid tumor malignancies of various organ systems (pulmonary/intrathoracic, cutaneous, head and neck, gastrointestinal, breast, genitourinary) who received ICI between 2012 and 2024. Propensity score matching was used to match cohorts for demographics, medical comorbidities, and oncologic staging. Primary outcome was overall survival (OS) up to 5 years and compared between obese body mass index (BMI; >30) and normal BMI (20-24.9) cohorts.
resultsAfter propensity score matching, there were a total of 18,434 patients, with 9217 patients in the obese BMI cohort and 9217 patients in the normal BMI cohort for all solid tumor malignancies. In the overall pan-cancer analysis, obese BMI was associated with significantly improved OS up to 5 years compared to the normal BMI cohort (hazard ratio [HR], 0.69 [0.66-0.72]). Subgroup analysis likewise demonstrated that obese BMI was associated with significantly improved OS up to 5 years for respiratory/intrathoracic (HR, 0.77 [0.72-0.83]), cutaneous (HR, 0.62 [0.63-0.78]), head and neck (HR, 0.67 [0.58-0.78]), gastrointestinal (HR, 0.67 [0.58-0.78]), breast (HR, 0.66 [0.55-0.79]), and genitourinary (HR, 0.57 [0.34-0.93]) malignancies (though not renal cell carcinoma specifically.)
conclusionsObesity was associated with improved 5-year OS after treatment with ICI across various solid tumor malignancies in this electronic health record-based big data study. Further investigation is warranted to understand the mechanism of this association.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.